Published in Pharm Res on July 01, 1998
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm (2013) 1.04
Self-titrating anticoagulant nanocomplexes that restore homeostatic regulation of the coagulation cascade. ACS Nano (2014) 0.93
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis. ACS Chem Neurosci (2011) 0.89
Engineering antiphagocytic biomimetic drug carriers. Ther Deliv (2013) 0.79
Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent. Int J Nanomedicine (2013) 0.78
Polysaccharide nanosystems for future progress in cardiovascular pathologies. Theranostics (2014) 0.78
Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers. Pharm Res (2009) 0.77
Application of polysaccharides for surface modification of nanomedicines. Ther Deliv (2012) 0.77
O-hexadecyl-dextran entrapped berberine nanoparticles abrogate high glucose stress induced apoptosis in primary rat hepatocytes. PLoS One (2014) 0.76
In vitro evaluation of poly(caporlactone) grafted dextran (PGD) nanoparticles with cancer cell. J Mater Sci Mater Med (2007) 0.76
Nanoprecipitation of polymeric nanoparticle micelles based on 2-methacryloyloxyethyl phosphorylcholine (MPC) with 2-(diisopropylamino)ethyl methacrylate (DPA), for intracellular delivery applications. J Mater Sci Mater Med (2015) 0.75
Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery. J Control Release (2015) 0.75
Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res (2001) 1.48
Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials (2001) 1.46
In vitro release kinetic pattern of indomethacin from poly(D,L-lactide) nanocapsules. J Pharm Sci (1990) 1.12
In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188. Antimicrob Agents Chemother (2000) 1.03
Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials (1996) 1.03
Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci (1997) 0.98
Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J Pharm Sci (1986) 0.97
Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res (1999) 0.97
Poly(D,L-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. J Pharm Sci (2000) 0.97
Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother Pharmacol (1990) 0.96
Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces. Eur J Immunol (1989) 0.94
Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res (1992) 0.93
Influence of sterilization processes on poly(epsilon-caprolactone) nanospheres. Biomaterials (1997) 0.92
The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice. Trop Med Parasitol (1994) 0.92
Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution. Int J Pharm (2007) 0.91
Thrombosis of angiographic catheters in humans: experimental study. Int J Artif Organs (1999) 0.90
Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci (1998) 0.89
Periodate oxidation of sodium alginate in water and in ethanol-water mixture: a comparative study. Carbohydr Res (2005) 0.89
Interactions between a macrophage cell line (J774A1) and surface-modified poly (D,L-lactide) nanocapsules bearing poly(ethylene glycol). J Drug Target (1999) 0.87
Study of the toxicity of a new lipid complex formulation of amphotericin B. J Antimicrob Chemother (2003) 0.86
In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres. J Drug Target (2002) 0.86
Strategies for the design of orally bioavailable antileishmanial treatments. Int J Pharm (2013) 0.85
Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J Control Release (2000) 0.85
Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell (1987) 0.85
Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(d,l-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm Res (1991) 0.85
Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers. Antimicrob Agents Chemother (2001) 0.84
Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother (2003) 0.84
Pharmacokinetic evaluation of indomethacin nanocapsules. Drug Des Deliv (1989) 0.83
Influence of poly(DL-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Pharm Res (1993) 0.83
Development of an injectable formulation of albendazole and in vivo evaluation of its efficacy against Echinococcus multilocularis metacestode. Int J Parasitol (1995) 0.83
Regulation by sulphonate groups of complement activation induced by hydroxymethyl groups on polystyrene surfaces. Biomaterials (1993) 0.82
Modulation of nitric oxide production in RAW 264.7 cells by transforming growth factor-beta and interleukin-10: differential effects on free and encapsulated immunomodulator. J Leukoc Biol (1997) 0.82
The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives. Mol Immunol (1988) 0.82
In vitro and in vivo antitumoral activity of free, and encapsulated taxol. J Microencapsul (1990) 0.81
Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system. Biomaterials (1997) 0.81
Anticoagulant effects of sulphonated polyurethanes. Biomaterials (1992) 0.80
A new generation of polymer nanoparticles for drug delivery. Cell Mol Biol (Noisy-le-grand) (2004) 0.80
Preparation and in vivo studies of a new drug delivery system. Nanoparticles of alkylcyanoacrylate. Appl Biochem Biotechnol (1984) 0.80
Interactions of functionalized polystyrene derivatives with the complement system in human serum. J Biomater Sci Polym Ed (1991) 0.80
Oxidized chondroitin sulfate-cross-linked gelatin matrixes: a new class of hydrogels. Biomacromolecules (2005) 0.80
How to concentrate nanoparticles and avoid aggregation? Eur J Pharm Biopharm (2008) 0.79
Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet (1993) 0.79
Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability. Int J Pharm (2007) 0.79
Heparin-like activity of insoluble sulphonated polystyrene resins. Part III: Binding of dicarboxylic amino acids. Biomaterials (1987) 0.78
Heparin-like functionalized polymer surfaces: discrimination between catalytic and adsorption processes during the course of thrombin inhibition. Biomaterials (1996) 0.78
Reduction of the uptake by a macrophagic cell line of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J Drug Target (2000) 0.78
The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro. Ann Trop Med Parasitol (2001) 0.78
Factors influencing macrophage activation by muramyl peptides: inhibition of NO synthase activity by high levels of NO. Biochim Biophys Acta (1994) 0.78
Poly(D,L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Pharm Res (1995) 0.78
Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta (1986) 0.78
Pharmacokinetics of D-Trp6 LHRH in man: sustained release polymer microsphere study (I.M. route). Prog Clin Biol Res (1987) 0.77
Specific interactions of polystyrene biomaterials with factor D of human complement. Biomaterials (1993) 0.77
Wound contractions, scar contractures and myofibroblasts: a classical case study. J Trauma (1978) 0.77
[Evolution of the pelvis and hip throughout history: from primates to modern man]. J Radiol (2011) 0.77
Interactions between human plasma proteins and heparin-poly(methyl methacrylate) copolymer. Thromb Haemost (1979) 0.76
Complement activation and adsorption of protein fragments by functionalized polymer surfaces in human serum. Biomaterials (1992) 0.76
Skin localization of cow's milk proteins delivered by a new ready-to-use atopy patch test. Pharm Res (2005) 0.76
Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. Int J Immunopharmacol (1997) 0.76
Relationship between reduction of complement activation by polysaccharide surfaces bearing diethylaminoethyl groups and their degree of substitution. Biomaterials (1995) 0.76
In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. J Antimicrob Chemother (1996) 0.76
Preparation and characterization of nanoparticles bearing heparin or dextran covalently-linked to poly(methyl methacrylate). J Biomater Sci Polym Ed (1999) 0.76
[Long circulating nanocapsules: interest in the treatment of severe malaria with halofantrine]. Ann Pharm Fr (2003) 0.75
Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleates. Colloids Surf B Biointerfaces (2013) 0.75
Formulation of shear rate sensitive multiple emulsions. J Control Release (2001) 0.75
Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules. Int J Immunopharmacol (1994) 0.75
[Evaluation of film forming properties of a hydroxypropylmethylcellulose phthalate (HP 55) pseudolatex]. J Pharm Belg (2000) 0.75
Role of the descending pressor pathway in the conscious and pentobarbital-anesthetized dog. Am J Physiol (1978) 0.75
[Determination of an intrinsic value of diffusion coefficient of active principle in polymeric matrix for the formulation of a controlled release system]. Ann Pharm Fr (1992) 0.75
A novel muramyl peptide derivative stimulates tumoricidal activity of macrophages and antibody production by B cells. FEBS Lett (1987) 0.75
The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker. Pharm Res (1991) 0.75
Biodegradable nanocapsules containing a lipophilic immunomodulator: drug retention and tolerance towards macrophages in vitro. J Drug Target (1993) 0.75
Properties of heparin--poly(methyl methacrylate) copolymers. II. J Biomed Mater Res (1977) 0.75
[The chronically limping child]. J Radiol (2011) 0.75
Optimization and characterization of freeze-dried multilamellar liposomes incorporating different standardized allergen extracts. Allergy (1994) 0.75
Anti-metastatic activity in vivo of MDP-L-alanyl-cholesterol (MTP-Chol) entrapped in nanocapsules. Int J Immunopharmacol (1991) 0.75
Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules. Int J Immunopharmacol (1994) 0.75
Activation of macrophages to tumour cytotoxicity by bacterial products. Ann Inst Pasteur Immunol (1986) 0.75
Determining the microbiological criteria for lot rejection from the performance objective or food safety objective. Int J Food Microbiol (2006) 0.75
Poly(rac-lactide) nanocapsules containing diclofenac: protection against muscular damage in rats. J Biomater Sci Polym Ed (2000) 0.75
Preparation and characterization of dipalmitoylphosphatidylcholine liposomes containing interleukin-2. Braz J Med Biol Res (1995) 0.75
Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives. J Med Chem (1996) 0.75
Liposomal formulations for oral immunotherapy: in-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse. J Drug Target (1998) 0.75
Diffusion MRI of the neck of the femur in Legg-Calve-Perthes disease: a preliminary study. Diagn Interv Imaging (2012) 0.75
[Alkaloids of Voacanga. V. N-oxy-voacamine]. Bull Soc Chim Fr (1967) 0.75
Effect on cerebral blood flow of orally administered indomethacin-loaded poly(isobutylcyanoacrylate) and poly(DL-lactide) nanocapsules. J Pharm Pharmacol (1990) 0.75